Mizuho Reiterates Corbus Pharmaceuticals (CRBP) at Outperform, 'see a buying opportunity'
Tweet Send to a Friend
Mizuho analyst Graig Suvannavejh reiterated an Outperform rating and $74.00 price target on Corbus Pharmaceuticals (NASDAQ: CRBP).The analyst commented: "CRBP ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
